SARS-CoV-2 Droplet and Airborne Transmission Heterogeneity
Overview
Affiliations
The spread dynamics of the SARS-CoV-2 virus have not yet been fully understood after two years of the pandemic. The virus's global spread represented a unique scenario for advancing infectious disease research. Consequently, mechanistic epidemiological theories were quickly dismissed, and more attention was paid to other approaches that considered heterogeneity in the spread. One of the most critical advances in aerial pathogens transmission was the global acceptance of the airborne model, where the airway is presented as the epicenter of the spread of the disease. Although the aerodynamics and persistence of the SARS-CoV-2 virus in the air have been extensively studied, the actual probability of contagion is still unknown. In this work, the individual heterogeneity in the transmission of 22 patients infected with COVID-19 was analyzed by close contact (cough samples) and air (environmental samples). Viral RNA was detected in 2/19 cough samples from patient subgroups, with a mean Ct (Cycle Threshold in Quantitative Polymerase Chain Reaction analysis) of 25.7 ± 7.0. Nevertheless, viral RNA was only detected in air samples from 1/8 patients, with an average Ct of 25.0 ± 4.0. Viral load in cough samples ranged from 7.3 × 10 to 8.7 × 10 copies/mL among patients, while concentrations between 1.1-4.8 copies/m were found in air, consistent with other reports in the literature. In patients undergoing follow-up, no viral load was found (neither in coughs nor in the air) after the third day of symptoms, which could help define quarantine periods in infected individuals. In addition, it was found that the patient's Ct should not be considered an indicator of infectiousness, since it could not be correlated with the viral load disseminated. The results of this work are in line with proposed hypotheses of superspreaders, which can attribute part of the heterogeneity of the spread to the oversized emission of a small percentage of infected people.
Garrec C, Arrindell J, Andrieu J, Desnues B, Mege J, Omar Osman I PLoS One. 2025; 20(2):e0313068.
PMID: 39928619 PMC: 11809792. DOI: 10.1371/journal.pone.0313068.
COVID-19: An overview on possible transmission ways, sampling matrices and diagnosis.
Armani Khatibi E, Farshbaf Moghimi N, Rahimpour E Bioimpacts. 2024; 14(6):29968.
PMID: 39493896 PMC: 11530968. DOI: 10.34172/bi.2024.29968.
Biochemical rationale for transfusion of high titre COVID-19 convalescent plasma.
Verbrugghe C, Wouters E, Devloo R, Nurmi V, Seghers S, De Bleser D Sci Rep. 2024; 14(1):23579.
PMID: 39384892 PMC: 11464705. DOI: 10.1038/s41598-024-75093-x.
Shipley R, Seekings A, Byrne A, Shukla S, James J, Goharriz H J Gen Virol. 2024; 105(9).
PMID: 39292223 PMC: 11410047. DOI: 10.1099/jgv.0.002022.
Wu Y, Liu Z, Mao S, Liu B, Tong Z Int J Mol Sci. 2023; 24(4).
PMID: 36834622 PMC: 9967019. DOI: 10.3390/ijms24043209.